Group RPH and gate-Startup OncoBeta GmbH sign agreement for Sales Referral and Distribution of Rhenium-SCT® in Brazil

OncoBeta® GmbH, a commercial stage Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs) and located at gate Garching, is pleased to announce today that it has entered an exclusive Sales Referral and Distribution agreement with Grupo RPH to start Rhenium-SCT® (Skin Cancer Therapy) treatments in Brazil.

As a leading brand in the Brazilian nuclear medicine market and one of the biggest of the sector in Latin America, Grupo RPH will employ its extensive knowledge on this area to introduce, distribute and service the Rhenium-SCT® therapy in Brazil. Under this agreement, Grupo RPH and OncoBeta® GmbH will work together sharing one mission: to promote the quality of life to patients with non-melanoma skin cancer.

The global incidence of non-melanoma skin cancers has been drastically increasing over the past decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. NMSC is one of the most common forms of cancer in Brazil. Presently the number of newly diagnosed cases in Brazil is approximately 200,000 annually. It is expected that this number will increase dramatically over the next few years.

Grupo RPH Managing Director, Rafael Madke stated, “Grupo RPH is very glad to establish the partnership with OncoBeta® GmbH. The Rhenium-SCT® is a ground-breaking technology that will change the therapeutic practice of non-melanoma skin cancer. This agreement sets the start of a long-term partnership between Grupo RPH and OncoBeta® GmbH to bring other innovative technologies to Brazil”

“This partnership and cooperation brings a fantastic opportunity to patients suffering from skin cancer in Brazil who will soon be able to be treated with the Rhenium-SCT® .” states Shannon D. Brown III, CEO and Managing Director of OncoBeta® GmbH. “We are very excited to be able to join forces with a leader in the nuclear medicine market in Latin America such as Grupo RPH which is a further step in making the Rhenium-SCT® more accessible to patients worldwide".

About the Rhenium-SCT® (Skin Cancer Therapy)

The Rhenium-SCT® is a non-invasive, painless therapy generally providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat. The Rhenium-SCT® utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). Due to the specially designed devices and accessories the Rhenium-SCT® compound never comes in direct contact with the patients’ skin and the application is safe and simple for the applying physician. Most cases of non-melanoma skin cancers (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT® with a single application, applied in one single session. Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.

About Grupo RPH

Operating since 2004, Grupo RPH commercially delivers eight different Cold Kits for Tc99m and Ga68 preparation for the Brazilian market. Grupo RPH is also the proud owner of the only private-owned fully GMP production facility in Brazil for nuclear medicine products. Grupo RPH’s products are sold throughout the whole Brazilian territory, serving nearly 400 customers on a daily basis. Grupo RPH is also a pioneer of the Centralized Radiopharmacy model in Brazil.

For more information visit

About OncoBeta® GmbH

OncoBeta® GmbH with its headquarters located at the Garching Technology and Founders Center GATE near Munich, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards.

Find out more about the Rhenium-SCT® at

About gate – Garchinger Technologie- und Gründerzentrum

As a business incubator the gate is the first place to go to for high-tech-startups and is located on the research campus in Garching/Munich. More than 50 resident gate startups mainly appreciate the flexibly expandable offices in direct neigbourhood to the Technical University of Munich. In order to become mature entrepreneurs, the founders seek the local coach’s advice and can resort to a network of research and specialists.

Founders who have innovative ideas, especially within the range of CleanTech, Artificial Intelligence, Industry 4.0, MedTech, IT, Virtual & Augmented Reality or Robotics, meet passionate like-minded people at the gate.

Since it’s foundation in 2002, gate has supported more than 300 companies. This total package, subsidised by the Bavarian government, makes it „the gate to success for high-tech-startups“.

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta’s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta’s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Firmenkontakt und Herausgeber der Meldung:

gate Garchinger Technologie- und Gründerzentrum GmbH
Lichtenbergstraße 8
85748 Garching bei München
Telefon: +49 (89) 5484-0
Telefax: +49 (89) 5484-1010

Lisa Hyna
Marketing & Öffentlichkeitsarbeit
Telefon: +49 (89) 5484-1110
Fax: +49 (89) 5484-1010
Für die oben stehende Pressemitteilung ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.